Spatial profiling of the metabolism-immune axis in ovarian cancer
Open Access
- 29 January 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16
Abstract
Ovarian cancer remains a lethal disease marked by profound therapeutic resistance, largely orchestrated by a complex tumor microenvironment (TME) governed by metabolism-immune crosstalk. This review focuses on the spatiotemporal dynamics of the metabolism-immune axis in ovarian cancer progression and resistance, with particular emphasis on how cutting-edge spatial multi-omics technologies reveal previously unrecognized layers of intratumoral heterogeneity and geographic organization that cannot be captured by bulk analyses. Using tools such as MALDI-MSI, GeoMx DSP, and CODEX, these approaches enable high-resolution, spatially resolved mapping of metabolite gradients (e.g., lactate, lipids, kynurenine), immune cell niches, and immunometabolic checkpoints within distinct tumor regions. Such spatial profiling uncovers how metabolic reprogramming-dysregulated glycolysis, lipid metabolism, and glutaminolysis-drives localized immunosuppression and chemoresistance through compartment-specific interactions among tumor cells, cancer-associated fibroblasts (CAFs), adipocytes, and immune populations. These geographically defined insights reshape our understanding of therapeutic failure and highlight precise, location-aware vulnerabilities. Accordingly, we propose spatially informed therapeutic strategies, including regional glycolysis inhibition, glutaminase blockade, lipid pathway interference, and their rational combination with immune checkpoint inhibitors (ICIs), to disrupt pathogenic metabolic-immune circuits and improve immunotherapy outcomes. Looking ahead, advances in vivo spatial imaging, gut microbiota modulation, and AI-powered integrative multi-omics frameworks promise truly personalized treatment of ovarian cancer.Keywords
This publication has 248 references indexed in Scilit:
- The Novel Dual GIP and GLP‐1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose MetabolismAdvanced Science, 2025
- Interpretable Multimodal Fusion Model for Bridged Histology and Genomics Survival Prediction in Pan‐CancerAdvanced Science, 2025
- The Inhibitory Effects of the Natural Stilbene Piceatannol on Lactate Transport In Vitro Mediated by Monocarboxylate TransportersMolecular Nutrition & Food Research, 2024
- A PET‐Surrogate Signature for the Interrogation of the Metabolic Status of Breast CancersAdvanced Science, 2024
- Myeloid‐Mas Signaling Modulates Pathogenic Crosstalk among MYC+CD63+Endothelial Cells, MMP12+Macrophages, and Monocytes in Acetaminophen‐Induced Liver InjuryAdvanced Science, 2024
- Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cellsHealth Science Reports, 2022
- Artificial intelligence‐driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi‐center integration analysisMolecular Oncology, 2022
- Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer TumorsJAMA Network Open, 2020
- Drug‐Loaded Mesoporous Tantalum Oxide Nanoparticles for Enhanced Synergetic Chemoradiotherapy with Reduced Systemic ToxicitySmall, 2016
- Stimulation of nuclear receptor peroxisome proliferator–activated receptor‐γ limits NF‐κB‐dependent inflammation in mouse cystic fibrosis biliary epitheliumHepatology, 2015